Abstract
Migraine is a chronic neurological disorder characterized by recurrent moderate to severe headaches, associated with a number of autonomic nervous system symptoms. Migraine constitutes 16% of primary headaches affecting 10-20% of general population according to International Headache Society. Typically the headache is unilateral (affecting one half of the head) and pulsating in nature, lasting from 2 to 72 hours. Associated symptoms may include nausea, vomiting, photophobia, phonophobia and the pain is generally aggravated by physical activity. Globally, approximately 15% of the population is affected by migraine at some point in life. Initial recommended management is with simple analgesics such as ibuprofen and acetaminophen for the headache, an antiemetic for the nausea, and the avoidance of triggers. Specific agents such as triptans or ergotamines may be used by those for whom simple analgesics are not effective. All the already available drugs have certain limitations. Either they are unable to produce complete relief or 30-40% patients are no responders or drugs produce adverse effects. A new class of drugs like angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists have recently been studied for their off label use in prophylaxis of migraine. Studies done so far, have shown results in favour of their clinical use because of the ability to reduce number of days with headache, number of days with migraine, hours with migraine, headache severity index, level of disability, improved Quality of life and decrease in consumption of specific or nonspecific analgesics. This article reviews the available evidence on the efficacy and safety of these drugs in prophylaxis of migraine. Relevent literatures were chosen, examining the efficacy of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for migraine prophylaxis.
References
Frediani F et al. Measure of negative impact of migraine on daily activities, social relationships and therapeutic approach. Neurol Sci 2004;25 Suppl 3:S249-250.
Martin S. Prevalence of migraine headache in Canada. CMAJ 2001;164:1481.
Ferrari MD. Migraine. Lancet 1998;351:1043- 1051.
The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24 (Suppl 1):1-152.
Bartleson JD, Cutrer FM (May 2010). "Migraine update. Diagnosis and treatment". Minn Med 93 (5): 36–41.
Stroke Association Factsheet 28, version 01 published April 2012, stroke.org.uk
http://www.nhsbsa.nhs.uk/Documents/July-Sept 09 ACE Inhibitors and AIIRAs.pdf
Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322:19-22.
Nandha R, Singh H. Renin angiotensin system: A novel target for migraine prophylaxis. Indian J Pharmacol 2012;44:157-60.
Silberstein S.D., Holland S., Freitag F., Dodick D.W., Argoff C., Ashman E, New Guidelines on Treating Migraine, American Academy of Neurology APRIL 23, 2012 2012;78:1337–1345.
Paterna S, Di Pasquale P, Martino S, Arrostuto A, Ingurgio NC, Parrinello G, et al. Captopril versus Placebo in the prevention of hemicranias without aura-A randomized double blind study. Clin Ter 1992;141:475-81.
Etminan M, Levine MA, Tomlinson G, Rochon PA. Efficacy of angiotensin II receptor antagonists in preventing headache systematic overview and meta-analysis. Am J Med 2002;112:642-6.
Gales BJ, Bailey EK, Reed AN, Gales MA. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. 2010 Feb; 44(2):360-6.
Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis□-□An open label study. Eur J Neurol 2007;14:701-3.
Bender WI. ACE inhibitors for prophylaxis of migraine headaches, Headache 1995;8:470-1.
Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. Department of Neurology and Clinical Neurophysiology, Norwegian University of Science and Technology JAMA. 2003 Jan 1;289(1):65-9.
Owada K. Efficacy of candesartan in the treatment of migraine in hypertensive patients. Hypertens Res 2004;27:441-6.
Diener HC, Gendolla A, Fruersenger A, Evers S, Straube A, Schumacher H, et al. Telmisartan in migraine prophylaxis: A randomized, placebo- controlled trial. Cephalalgia 2009;29:921-7.
Sonbolestan SA, Heshmat K, Javanmard SH, and Saadatnia M Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial Int J Prev Med. 2013 January; 4(1): 72–77.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array